CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: ZFP30 (ImmuneEditome ID:22835)

1. Gene summary of enriched editing regions for ZFP30

check button Gene summary
Gene informationGene symbol

ZFP30

Gene ID

22835

GeneSynonymsZNF745
GeneCytomap

19q13.12

GeneTypeprotein-coding
GeneDescriptionzinc finger protein 30 homolog|zinc finger protein 745
GeneModificationdate20230518
UniprotIDQ9Y2G7;D3Y2A0;K7EK76;K7EMM3;K7EPH5
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr19:37632929-37633671:-ENST00000392144.4ENSG00000120784.14ZFP30splicingAluSx1,AluSq2chr19:37632929-37633671:-.alignment
chr19:37636800-37637676:-ENST00000351218.5ENSG00000120784.14ZFP30intronicAluSg4,AluSz,AluSx1,L2bchr19:37636800-37637676:-.alignment
chr19:37636800-37637676:-ENST00000392144.4ENSG00000120784.14ZFP30intronicAluSg4,AluSz,AluSx1,L2bchr19:37636800-37637676:-.alignment
chr19:37636800-37637676:-ENST00000514101.5ENSG00000120784.14ZFP30intronicAluSg4,AluSz,AluSx1,L2bchr19:37636800-37637676:-.alignment
chr19:37636800-37637676:-ENST00000587809.4ENSG00000120784.14ZFP30intronicAluSg4,AluSz,AluSx1,L2bchr19:37636800-37637676:-.alignment
chr19:37636800-37637676:-ENST00000589018.4ENSG00000120784.14ZFP30intronicAluSg4,AluSz,AluSx1,L2bchr19:37636800-37637676:-.alignment


Top

2. Tumor-specific enriched editing regions for ZFP30


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
ENSG00000120784.14,ZFP30THCAEAG6.5748e-03image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot
chr19:37632929-37633671:-KIRPEER5.6550e-031.9227e-021.6334e+04image
ENSG00000120784.14,ZFP30KIRPEAG2.5433e-041.2245e-022.3599e+04image

Top

3. Enriched editing regions and immune related genes for ZFP30


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr19:37632929-37633671:-GBMEERENSG00000159346,ADIPOR10.27032.2738e-025.4573e-120.5103imageNNOP56NAGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY
chr19:37632929-37633671:-UCECEERENSG00000234009,RPL5P340.32182.4318e-023.2655e-080.4664imageNNNAT_cells_regulatory_(Tregs)GSVA_HALLMARK_HEME_METABOLISM
chr19:37632929-37633671:-TGCTEERENSG00000249532,RP11-148B6.10.42204.6931e-057.8206e-100.5048imageNNNAMacrophages_M2GSVA_HALLMARK_GLYCOLYSIS
chr19:37632929-37633671:-TGCTEERENSG00000238150,AC008753.30.41719.2196e-051.2595e-090.4994imageNNNANK_cells_activatedGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION
chr19:37632929-37633671:-TGCTEERENSG00000166783,KIAA0430-0.39791.5383e-044.1159e-07-0.4253imageNNOP56NAB_cells_naiveGSVA_HALLMARK_GLYCOLYSIS
chr19:37632929-37633671:-TGCTEERENSG00000167863,ATP5H0.39261.8762e-041.1417e-060.4102imageNNOP56NAT_cells_CD4_memory_restingGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION
chr19:37632929-37633671:-TGCTEERENSG00000203965,EFCAB7-0.38782.6634e-041.9194e-06-0.4022imageNNOP56NAT_cells_CD4_memory_restingGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION
chr19:37632929-37633671:-TGCTEERENSG00000141429,GALNT1-0.38364.4085e-044.0339e-07-0.4256imageNNOP56NAT_cells_CD4_memory_restingGSVA_HALLMARK_BILE_ACID_METABOLISM
chr19:37632929-37633671:-TGCTEERENSG00000128272,ATF40.38064.8365e-042.0297e-080.4660imageNNOP56ATF4B_cells_naiveGSVA_HALLMARK_MITOTIC_SPINDLE
chr19:37632929-37633671:-TGCTEERENSG00000205358,MT1H0.37465.1424e-041.3157e-060.4080imageNNNAT_cells_CD4_memory_restingGSVA_HALLMARK_MTORC1_SIGNALING

More results



Top

4. Enriched editing regions and immune related splicing for ZFP30


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
ENSG00000120784.14,ZFP30
TGCTEAGIRENSG00000145604.11chr536177138:36177292:36183839:36184029-0.30143.1698e-023.8823e-06-0.4027imageNACIN1;ADAR;AIFM1;AUH;BUD13;CAPRIN1;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP4B;LIN28;LIN28A;LIN28B;MBNL2;MOV10;MSI1;MSI2;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RC3H1;RTCB;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;YTHDC1;YTHDF1;ZC3H7B;ZFP36;ZNF184SKP2B_cells_naiveGSVA_HALLMARK_GLYCOLYSIS
ENSG00000120784.14,ZFP30
TGCTEAGIRENSG00000168672.3chr8126552814:126553503:126556264:126556271-0.29192.4969e-021.2310e-05-0.4036imageNADAR;AIFM1;BCCIP;CAPRIN1;CELF2;CSTF2T;DDX54;DGCR8;EIF4A3;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FUS;FXR2;HNRNPA1;HNRNPC;HNRNPD;HNRNPM;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS2;LIN28;LIN28A;LIN28B;MBNL2;MOV10;NUMA1;PCBP2;PRPF8;RANGAP1;RBFOX2;RTCB;SRSF1;TIA1;TIAL1;U2AF2;UPF1;YTHDC1;YTHDF1;ZC3H7B;ZNF184NAT_cells_CD4_memory_restingGSVA_HALLMARK_MITOTIC_SPINDLE
chr19:37632929-37633671:-
TGCTEERIRENSG00000168672.3chr8126552814:126553503:126556264:126556271-0.29492.5129e-021.3893e-05-0.4014imageNNNAT_cells_CD4_memory_restingGSVA_HALLMARK_MITOTIC_SPINDLE
ENSG00000120784.14,ZFP30
TGCTEAGIRENSG00000174720.11chr4112646790:112647549:112647689:1126478340.36643.8461e-032.3267e-070.4334imageNACIN1;ADAR;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP4B;LIN28;LIN28A;LIN28B;MOV10;MSI2;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;RBFOX2;RBM10;SAFB2;SF3A3;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;YTHDC1;YTHDF1;ZC3H7B;ZFP36;ZNF184NAMacrophages_M2GSVA_HALLMARK_GLYCOLYSIS
chr19:37632929-37633671:-
TGCTEERIRENSG00000174720.11chr4112646790:112646955:112647033:1126471270.42904.4022e-044.5513e-070.4238imageNNOP56NAT_cells_CD4_memory_restingGSVA_HALLMARK_GLYCOLYSIS
ENSG00000120784.14,ZFP30
TGCTEAGESENSG00000161999.7chr16682771:682874:682952:683087:683166:683234-0.33161.4258e-022.3873e-06-0.4002imageNACIN1;AIFM1;AUH;BCCIP;BUD13;CNBP;CPSF6;CSTF2T;DDX3X;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;ELAVL1;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GTF2F1;HNRNPA2B1;HNRNPK;HNRNPL;HNRNPM;HNRNPU;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;LARP4B;LIN28;LIN28A;LIN28B;MOV10;MSI1;MSI2;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RC3H1;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF7;SRSF9;TAF15;TARDBP;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;YTHDC1;YTHDF1;ZC3H7B;ZNF184NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_MTORC1_SIGNALING
ENSG00000120784.14,ZFP30
TGCTEAGIRENSG00000174720.11chr4112646790:112647549:112647650:1126478340.39674.6781e-049.1396e-070.4195imageNACIN1;ADAR;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP4B;LIN28;LIN28A;LIN28B;MOV10;MSI2;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;RBFOX2;RBM10;SAFB2;SF3A3;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;YTHDC1;YTHDF1;ZC3H7B;ZFP36;ZNF184NAB_cells_naiveGSVA_HALLMARK_GLYCOLYSIS
chr19:37632929-37633671:-
TGCTEERIRENSG00000171067.6chr1168261608:68261725:68262730:68262918-0.36836.6865e-035.1067e-07-0.4222imageNNOP56NANK_cells_activatedGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION
ENSG00000120784.14,ZFP30
TGCTEAGA3ENSG00000174720.11chr4112646889:112646955:112647052:112647127:112647033:1126471270.36134.1940e-031.2875e-090.4992imageNACIN1;ADAR;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP4B;LIN28;LIN28A;LIN28B;MOV10;MSI2;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;RBFOX2;RBM10;SAFB2;SF3A3;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;YTHDC1;YTHDF1;ZC3H7B;ZFP36;ZNF184NAB_cells_naiveGSVA_HALLMARK_GLYCOLYSIS
chr19:37632929-37633671:-
TGCTEERIRENSG00000145604.11chr536177138:36177292:36183839:36184029-0.31112.6295e-023.7350e-06-0.4033imageNNOP56SKP2B_cells_naiveGSVA_HALLMARK_GLYCOLYSIS

More results



Top

5. Enriched editing regions and immune infiltration for ZFP30


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chr19:37632929-37633671:-BLCAEERB_cells_memory2.3581e-030.1958image
ENSG00000120784.14,ZFP30BLCAEAGB_cells_memory2.4050e-030.1927image
chr19:37632929-37633671:-BRCAEERMacrophages_M02.8678e-020.0699image
chr19:37632929-37633671:-CESCEERNK_cells_resting4.5258e-020.1571image
ENSG00000120784.14,ZFP30CESCEAGNK_cells_resting4.3902e-020.1580image
chr19:37632929-37633671:-COADEERMacrophages_M14.3928e-02-0.1990image
ENSG00000120784.14,ZFP30COADEAGMacrophages_M14.6944e-02-0.1963image
chr19:37632929-37633671:-ESCAEERDendritic_cells_resting4.5005e-020.4417image
ENSG00000120784.14,ZFP30ESCAEAGDendritic_cells_resting3.1190e-020.3648image
chr19:37632929-37633671:-HNSCEERNK_cells_activated5.3174e-030.2459image
ENSG00000120784.14,ZFP30HNSCEAGNK_cells_activated6.0305e-030.2406image
chr19:37632929-37633671:-KICHEEREosinophils2.0763e-020.3401image
ENSG00000120784.14,ZFP30KICHEAGEosinophils2.0848e-020.3398image
chr19:37632929-37633671:-KIRPEERT_cells_CD4_naive1.8984e-030.2929image
ENSG00000120784.14,ZFP30KIRPEAGT_cells_CD4_naive1.0392e-030.2982image
chr19:37632929-37633671:-LGGEERDendritic_cells_resting3.3095e-040.1658image
ENSG00000120784.14,ZFP30LGGEAGDendritic_cells_resting3.2592e-040.1649image
chr19:37632929-37633671:-LIHCEERNeutrophils2.3366e-040.4052image
ENSG00000120784.14,ZFP30LIHCEAGT_cells_regulatory_(Tregs)4.0065e-03-0.2989image
chr19:37632929-37633671:-LUADEERMast_cells_activated8.6406e-030.1592image
ENSG00000120784.14,ZFP30LUADEAGMacrophages_M06.1040e-030.1644image
chr19:37632929-37633671:-LUSCEERT_cells_CD4_memory_resting1.4107e-02-0.1518image
ENSG00000120784.14,ZFP30LUSCEAGT_cells_CD4_memory_resting6.9510e-03-0.1654image
chr19:37632929-37633671:-MESOEERB_cells_memory1.9375e-020.3828image
chr19:37632929-37633671:-OVEERMast_cells_activated3.2727e-020.1658image
ENSG00000120784.14,ZFP30OVEAGT_cells_CD81.1059e-020.1821image
chr19:37632929-37633671:-PAADEERT_cells_CD4_memory_resting3.3627e-020.2897image
ENSG00000120784.14,ZFP30PAADEAGT_cells_CD82.7369e-02-0.2897image
ENSG00000120784.14,ZFP30PCPGEAGT_cells_CD4_memory_activated3.6987e-02-0.1740image
chr19:37632929-37633671:-PRADEERDendritic_cells_resting1.3982e-030.1719image
ENSG00000120784.14,ZFP30PRADEAGDendritic_cells_resting1.8532e-030.1658image
chr19:37632929-37633671:-READEERNeutrophils2.5842e-02-0.3819image
ENSG00000120784.14,ZFP30READEAGNeutrophils4.5117e-02-0.3408image
ENSG00000120784.14,ZFP30SARCEAGNK_cells_activated4.6221e-02-0.1500image
chr19:37632929-37633671:-SKCMEERDendritic_cells_resting2.3096e-020.1571image
ENSG00000120784.14,ZFP30SKCMEAGDendritic_cells_resting1.3954e-020.1659image
chr19:37632929-37633671:-TGCTEERDendritic_cells_activated1.6437e-040.3234image
ENSG00000120784.14,ZFP30TGCTEAGDendritic_cells_activated1.2102e-040.3284image
chr19:37632929-37633671:-THCAEERB_cells_naive4.1396e-02-0.0983image
chr19:37632929-37633671:-UCECEERT_cells_CD4_naive7.5911e-030.2359image
ENSG00000120784.14,ZFP30UCECEAGT_cells_CD4_naive5.3761e-030.2392image
chr19:37632929-37633671:-UCSEERT_cells_follicular_helper1.0048e-02-0.3539image
ENSG00000120784.14,ZFP30UCSEAGT_cells_follicular_helper3.9623e-02-0.2863image


Top

6. Enriched editing regions and immune gene sets for ZFP30


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
ENSG00000120784.14,ZFP30ACCGSVA_HALLMARK_KRAS_SIGNALING_DNEAG3.6035e-020.2834image
chr19:37632929-37633671:-ACCGSVA_HALLMARK_KRAS_SIGNALING_DNEER3.7164e-020.2844image
ENSG00000120784.14,ZFP30BLCAGSVA_HALLMARK_MITOTIC_SPINDLEEAG2.9267e-03-0.1889image
chr19:37632929-37633671:-BLCAGSVA_HALLMARK_MITOTIC_SPINDLEEER2.2407e-03-0.1968image
chr19:37632929-37633671:-BRCAGSVA_HALLMARK_XENOBIOTIC_METABOLISMEER4.8885e-030.0898image
ENSG00000120784.14,ZFP30BRCAGSVA_HALLMARK_PANCREAS_BETA_CELLSEAG1.5759e-030.1006image
ENSG00000120784.14,ZFP30CESCGSVA_HALLMARK_BILE_ACID_METABOLISMEAG2.0613e-02-0.1812image
chr19:37632929-37633671:-CESCGSVA_HALLMARK_BILE_ACID_METABOLISMEER1.8340e-02-0.1846image
chr19:37632929-37633671:-CHOLGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEER1.6395e-020.4846image
ENSG00000120784.14,ZFP30CHOLGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEAG1.5516e-020.4882image
chr19:37632929-37633671:-COADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER4.6778e-02-0.1964image
ENSG00000120784.14,ZFP30ESCAGSVA_HALLMARK_APICAL_JUNCTIONEAG1.0628e-030.5298image
chr19:37632929-37633671:-ESCAGSVA_HALLMARK_ANGIOGENESISEER6.0244e-030.5784image
ENSG00000120784.14,ZFP30GBMGSVA_HALLMARK_IL2_STAT5_SIGNALINGEAG1.8698e-040.2895image
chr19:37632929-37633671:-GBMGSVA_HALLMARK_MYOGENESISEER6.0010e-040.2684image
ENSG00000120784.14,ZFP30HNSCGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEAG2.2382e-02-0.2010image
chr19:37632929-37633671:-HNSCGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEER2.5759e-02-0.1979image
ENSG00000120784.14,ZFP30KICHGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSEEAG2.8659e-02-0.3228image
chr19:37632929-37633671:-KICHGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSEEER3.0384e-02-0.3196image
chr19:37632929-37633671:-KIRCGSVA_HALLMARK_HEDGEHOG_SIGNALINGEER1.0701e-02-0.1545image
ENSG00000120784.14,ZFP30KIRCGSVA_HALLMARK_MITOTIC_SPINDLEEAG2.0976e-02-0.1379image
chr19:37632929-37633671:-KIRPGSVA_HALLMARK_HEME_METABOLISMEER1.4852e-02-0.2317image
ENSG00000120784.14,ZFP30KIRPGSVA_HALLMARK_NOTCH_SIGNALINGEAG1.7763e-02-0.2179image
chr19:37632929-37633671:-LGGGSVA_HALLMARK_PROTEIN_SECRETIONEER2.4219e-02-0.1045image
ENSG00000120784.14,ZFP30LIHCGSVA_HALLMARK_HYPOXIAEAG4.9751e-030.2920image
chr19:37632929-37633671:-LIHCGSVA_HALLMARK_HYPOXIAEER3.9942e-020.2332image
chr19:37632929-37633671:-LUADGSVA_HALLMARK_MITOTIC_SPINDLEEER4.5042e-020.1219image
chr19:37632929-37633671:-LUSCGSVA_HALLMARK_G2M_CHECKPOINTEER3.8424e-02-0.1282image
ENSG00000120784.14,ZFP30MESOGSVA_HALLMARK_APICAL_SURFACEEAG1.9219e-020.3734image
chr19:37632929-37633671:-OVGSVA_HALLMARK_P53_PATHWAYEER1.5425e-020.1878image
ENSG00000120784.14,ZFP30OVGSVA_HALLMARK_P53_PATHWAYEAG2.1686e-030.2189image
ENSG00000120784.14,ZFP30PCPGGSVA_HALLMARK_MITOTIC_SPINDLEEAG1.1740e-02-0.2095image
chr19:37632929-37633671:-PCPGGSVA_HALLMARK_UV_RESPONSE_DNEER3.2737e-02-0.1826image
ENSG00000120784.14,ZFP30PRADGSVA_HALLMARK_P53_PATHWAYEAG7.1330e-030.1436image
chr19:37632929-37633671:-PRADGSVA_HALLMARK_P53_PATHWAYEER2.7384e-030.1613image
chr19:37632929-37633671:-SARCGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER3.0898e-020.1676image
ENSG00000120784.14,ZFP30TGCTGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEAG8.7931e-040.2862image
chr19:37632929-37633671:-TGCTGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEER6.7402e-040.2933image
ENSG00000120784.14,ZFP30THCAGSVA_HALLMARK_PROTEIN_SECRETIONEAG1.2940e-03-0.1536image
chr19:37632929-37633671:-THCAGSVA_HALLMARK_ANDROGEN_RESPONSEEER7.9754e-04-0.1610image
chr19:37632929-37633671:-THYMGSVA_HALLMARK_UV_RESPONSE_DNEER1.1522e-03-0.3391image
ENSG00000120784.14,ZFP30THYMGSVA_HALLMARK_UV_RESPONSE_DNEAG1.8433e-03-0.3239image
chr19:37632929-37633671:-UCECGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEER2.4891e-020.1990image
chr19:37632929-37633671:-UCSGSVA_HALLMARK_MITOTIC_SPINDLEEER2.2232e-03-0.4150image
ENSG00000120784.14,ZFP30UCSGSVA_HALLMARK_MITOTIC_SPINDLEEAG1.2682e-02-0.3434image


Top

7. Enriched editing regions and drugs for ZFP30


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
chr19:37632929-37633671:-BLCAAZD6482EER2.1845e-030.1973image
ENSG00000120784.14,ZFP30BLCAAZD6482EAG2.7884e-030.1899image
chr19:37632929-37633671:-BRCAJNK.Inhibitor.VIIIEER7.4181e-040.1076image
ENSG00000120784.14,ZFP30BRCAJNK.Inhibitor.VIIIEAG3.3907e-030.0933image
chr19:37632929-37633671:-CESCAZD6482EER4.7883e-030.2199image
ENSG00000120784.14,ZFP30CESCAZD6482EAG2.8136e-030.2326image
chr19:37632929-37633671:-CHOLAZD.2281EER3.7971e-03-0.5790image
ENSG00000120784.14,ZFP30CHOLAZD.2281EAG3.5806e-03-0.5819image
chr19:37632929-37633671:-COADAZD.2281EER3.6122e-020.2068image
ENSG00000120784.14,ZFP30COADAZD.2281EAG3.4758e-020.2083image
ENSG00000120784.14,ZFP30ESCAGSK269962AEAG6.5061e-05-0.6226image
chr19:37632929-37633671:-ESCAGSK269962AEER2.7879e-05-0.7823image
ENSG00000120784.14,ZFP30GBMBicalutamideEAG4.6706e-05-0.3142image
chr19:37632929-37633671:-GBMBicalutamideEER6.2808e-05-0.3109image
ENSG00000120784.14,ZFP30HNSCBAY.61.3606EAG1.1878e-020.2209image
chr19:37632929-37633671:-HNSCBAY.61.3606EER1.1710e-020.2231image
ENSG00000120784.14,ZFP30KICHGNF.2EAG3.8387e-02-0.3064image
chr19:37632929-37633671:-KICHGNF.2EER4.1772e-02-0.3014image
ENSG00000120784.14,ZFP30KIRCAZD8055EAG7.0852e-030.1606image
chr19:37632929-37633671:-KIRCAZD8055EER9.7096e-030.1566image
ENSG00000120784.14,ZFP30KIRPEmbelinEAG3.0202e-020.1996image
chr19:37632929-37633671:-KIRPEmbelinEER8.4440e-030.2500image
chr19:37632929-37633671:-LGGJNK.Inhibitor.VIIIEER2.0480e-030.1426image
ENSG00000120784.14,ZFP30LGGJNK.Inhibitor.VIIIEAG7.2800e-030.1235image
chr19:37632929-37633671:-LUADJNK.Inhibitor.VIIIEER1.7060e-02-0.1448image
ENSG00000120784.14,ZFP30LUADJNK.Inhibitor.VIIIEAG1.7567e-02-0.1426image
ENSG00000120784.14,ZFP30LUSCLFM.A13EAG2.0568e-02-0.1422image
chr19:37632929-37633671:-LUSCImatinibEER2.5367e-02-0.1384image
chr19:37632929-37633671:-MESODoxorubicinEER7.7915e-03-0.4307image
ENSG00000120784.14,ZFP30MESODoxorubicinEAG2.2307e-03-0.4753image
ENSG00000120784.14,ZFP30OVBIRB.0796EAG9.9325e-03-0.1847image
chr19:37632929-37633671:-OVMidostaurinEER9.1718e-03-0.2017image
chr19:37632929-37633671:-PAADA.770041EER4.7509e-020.2762image
chr19:37632929-37633671:-PRADA.770041EER1.0228e-04-0.2085image
ENSG00000120784.14,ZFP30PRADA.770041EAG2.2774e-04-0.1961image
ENSG00000120784.14,ZFP30SARCCytarabineEAG6.0617e-030.2055image
chr19:37632929-37633671:-SARCGNF.2EER1.4483e-03-0.2453image
chr19:37632929-37633671:-SKCMCHIR.99021EER8.5830e-03-0.1814image
ENSG00000120784.14,ZFP30SKCMCHIR.99021EAG3.6064e-03-0.1959image
ENSG00000120784.14,ZFP30STADAZD.0530EAG4.3754e-02-0.2096image
chr19:37632929-37633671:-STADBryostatin.1EER1.8219e-03-0.3497image
chr19:37632929-37633671:-TGCTMG.132EER3.8303e-04-0.3058image
ENSG00000120784.14,ZFP30TGCTMG.132EAG3.2825e-04-0.3079image
ENSG00000120784.14,ZFP30THCABMS.708163EAG9.4645e-050.1859image
chr19:37632929-37633671:-THCACEP.701EER5.6086e-05-0.1928image
ENSG00000120784.14,ZFP30THYMBMS.509744EAG1.3701e-04-0.3913image
chr19:37632929-37633671:-THYMBMS.509744EER2.7907e-05-0.4286image
chr19:37632929-37633671:-UCECJNK.Inhibitor.VIIIEER1.0632e-040.3371image
ENSG00000120784.14,ZFP30UCECJNK.Inhibitor.VIIIEAG4.9893e-030.2412image
chr19:37632929-37633671:-UCSEmbelinEER9.6315e-030.3558image
ENSG00000120784.14,ZFP30UCSBMS.536924EAG2.0619e-02-0.3203image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType